TENX on XNAS, Health Care, Tenax Therapeutics, Inc., job postings
Measures activity, not value. Not investment advice.
Shares fell 84% in 12 months while insiders bought $6.4M and short interest is 31 times a year earlier.
BadNet loss of $65.8M over 12 months; cash on hand $113.7M
Written by AI from the data on this page, 22 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.
expected around 9 Mar 2027 (an estimate: a year ago it reported on 10 Mar 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $0, net loss $16.7M.
31 Dec 2021RevenueNet incomeNet losstallest bar $61.7M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$0
-$16.7M
30 Jun 2026
$0
-$17.8M
31 Mar 2026
$0
-$15.7M
31 Dec 2025
$0
-$15.5M
30 Sep 2025
$0
-$15.8M
30 Jun 2025
$0
-$10.8M
31 Mar 2025
$0
-$10.4M
30 Sep 2024
–
$4.0M
30 Jun 2024
–
$3.6M
31 Mar 2024
–
$3.8M
30 Sep 2023
–
$2.0M
30 Jun 2023
–
-$1.1M
31 Mar 2023
–
$1.4M
31 Dec 2022
–
-$19.5M
30 Sep 2022
–
$2.9M
30 Jun 2022
–
$2.9M
31 Mar 2022
–
-$2.7M
31 Dec 2021
–
-$61.7M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
–
–
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
–
+11%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
-$65.8M
-$43.3M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
-$1.39
-$0.73
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
–
–
73.2%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
–
–
-25.0%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
–
–
-18.2%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
-64.2%
-58.8%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
–
–
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$113.7M
$99.4M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$0
–
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$113.7M (net cash)
–
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.0
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$2.39
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
loss
19.3
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
–
5.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
–
5.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
0.52
2.0
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
+$6.4M
bought $6.4M, sold $0
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
-5.4%
105 13F filers vs 111
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
70%
31.9M shares held by 13F filers (30 Sep 2026) of 45.5M outstanding (31 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
13%
5.8M shares sold short (30 Oct 2026) of 45.5M outstanding (31 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
3.2
5.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-20%
7.2M shares sold short in the report before, 5.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
33%
33% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 38%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
–
No data for this company
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
–
No data for this company
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
–
No data for this company
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
–
No data for this company
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
–
No data for this company
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
26
26 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
8.7×
26 articles in the last 7 days; its usual week has 3.
Unusual now sharp changes in the last 90 days, compared with its own past
Short interest 9.3M, 31× a year earlier
Insider buying $4.8M, 3 insiders
Price $1.25 on 20 Nov 2026, -84% over 12 months (12-month range $1.25 to $18.32)
Sharp change
8-K and other filings
Insider net buying (open market). Insiders bought a net $6.5M in the last 12 months (the 12 months before: $93K).Revenue per quarter. Revenue $0 in the latest quarter.Capital spending per quarter. Capital spending $2K in the latest quarter.Institutional holders (13F filers). 105 13F filers reported holding it in the latest 13F quarter, +218% on a year earlier.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: h-1b/e-3 applications certified, federal obligations, lobbying spend, workers in warn layoff notices.
Quarter ended 31 Mar 2025: $0; public on 15 May 2025
Quarter ended 30 Jun 2025: $0; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $0; public on 13 Nov 2025
Quarter ended 31 Dec 2025: $0; public on 11 Mar 2026
Quarter ended 31 Mar 2026: $0; public on 13 May 2026
Quarter ended 30 Jun 2026: $0; public on 1 Aug 2026
Quarter ended 30 Sep 2026: $0; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2021: $0; public on 17 May 2022
Quarter ended 31 Dec 2021: $2K, -51% on a year earlier; public on 30 Mar 2022
Quarter ended 30 Jun 2022: $0, -100% on a year earlier; public on 12 Aug 2022
Quarter ended 30 Sep 2022: $0, -100% on a year earlier; public on 11 Nov 2022
Quarter ended 31 Mar 2023: $1K; public on 16 May 2023
Quarter ended 30 Jun 2023: $2K; public on 15 Aug 2023
Institutional holders (13F filers)
31 Dec 2021 report: 28; public on 14 Feb 2022
31 Mar 2022 report: 25; public on 16 May 2022
30 Jun 2022 report: 25; public on 15 Aug 2022
30 Sep 2022 report: 27; public on 14 Nov 2022
31 Dec 2022 report: 18; public on 14 Feb 2023
31 Mar 2023 report: 13; public on 15 May 2023
30 Jun 2023 report: 13; public on 14 Aug 2023
30 Sep 2023 report: 13; public on 14 Nov 2023
31 Dec 2023 report: 16; public on 14 Feb 2024
31 Mar 2024 report: 8; public on 15 May 2024
30 Jun 2024 report: 11; public on 14 Aug 2024
30 Sep 2024 report: 19; public on 14 Nov 2024
31 Dec 2024 report: 21; public on 14 Feb 2025
31 Mar 2025 report: 23; public on 15 May 2025
30 Jun 2025 report: 24; public on 14 Aug 2025
30 Sep 2025 report: 33; public on 14 Nov 2025
31 Dec 2025 report: 45; public on 17 Feb 2026
31 Mar 2026 report: 78; public on 15 May 2026
30 Jun 2026 report: 111; public on 14 Aug 2026
30 Sep 2026 report: 105; public on 16 Nov 2026
What is unusual now
Made public in the last 90 days: it had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year; it also had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year. 7 sharp changes in all. Two or more unrelated kinds of activity agreed on 16 Sep 2026.
Short interest spike: had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year Public on 11 Sep 2026.
Two or more unrelated kinds of records unusual within 30 days
16 Sep 2026confirmed
Confirmed across sources Insiders and Short interest and volume
Tenax Therapeutics(TENX): had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year, while it had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings). Two unrelated kinds of activity within 91 days.
Short interest and volume: Short interest spike, became public on 12 Aug 2026
Short interest and volume: Short interest spike, became public on 26 Aug 2026
Short interest and volume: Short interest spike, became public on 11 Sep 2026
Insiders: Clustered insider buying, became public on 16 Sep 2026
Short interest and volume: Short interest spike, became public on 25 Sep 2026
Short interest and volume: Short interest spike, became public on 10 Oct 2026
Short interest and volume: Short interest spike, became public on 27 Oct 2026
Short interest and volume: Short interest spike, became public on 11 Nov 2026
The 31 Aug 2026 report against the 24 reports before it.
this reportearliernormal: 577KSee the evidence (8 changes)
Short interest and volume: Short interest spike became public on 12 Aug 2026
Tenax Therapeutics had 2.6M shares sold short in the 31 Jul 2026 report, 7.6× the same report last year.
This period
2.6M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
433K
Typical spread (median absolute deviation)
303K
How far from its usual level
+4.7
Same report last year
335K
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 433K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Aug 2026
Tenax Therapeutics had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year.
This period
5.5M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
542K
Typical spread (median absolute deviation)
258K
How far from its usual level
+12.9
Same report last year
327K
History used
3,150 days
the 14 Aug 2026 report24 earlier reportsnormal: 542K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2026
Tenax Therapeutics had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year.
This period
9.3M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
577K
Typical spread (median absolute deviation)
341K
How far from its usual level
+17.2
Same report last year
298K
History used
3,167 days
the 31 Aug 2026 report24 earlier reportsnormal: 577K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Insiders: Clustered insider buying became public on 16 Sep 2026
Tenax Therapeutics had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings).
Independent buyers
3
Purchase filings (Form 4, code P)
5
Total bought
$4.8M
Window
17 Aug 2026 to 16 Sep 2026
Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M)dated 24 Aug 2026, public 25 Aug 2026
Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M)dated 2 Sep 2026, public 3 Sep 2026
ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M)dated 8 Sep 2026, public 9 Sep 2026
Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107)dated 15 Sep 2026, public 16 Sep 2026
STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010)dated 15 Sep 2026, public 16 Sep 2026
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 25 Sep 2026
Tenax Therapeutics had 5.5M shares sold short in the 15 Sep 2026 report, 20× the same report last year.
This period
5.5M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
666K
Typical spread (median absolute deviation)
470K
How far from its usual level
+6.9
Same report last year
275K
History used
3,182 days
the 15 Sep 2026 report24 earlier reportsnormal: 666K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2026
Tenax Therapeutics had 7.2M shares sold short in the 30 Sep 2026 report, 13× the same report last year.
This period
7.2M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
743K
Typical spread (median absolute deviation)
559K
How far from its usual level
+7.8
Same report last year
554K
History used
3,197 days
the 30 Sep 2026 report24 earlier reportsnormal: 743K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Oct 2026
Tenax Therapeutics had 7.2M shares sold short in the 15 Oct 2026 report, 9.6× the same report last year.
This period
7.2M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
756K
Typical spread (median absolute deviation)
593K
How far from its usual level
+7.4
Same report last year
754K
History used
3,212 days
the 15 Oct 2026 report24 earlier reportsnormal: 756K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Nov 2026
Tenax Therapeutics had 5.8M shares sold short in the 30 Oct 2026 report, 7.6× the same report last year.
This period
5.8M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
760K
Typical spread (median absolute deviation)
622K
How far from its usual level
+5.5
Same report last year
762K
History used
3,227 days
the 30 Oct 2026 report24 earlier reportsnormal: 760K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
6 Dec 2025confirmed
Confirmed across sources Insiders and Short interest and volume
Tenax Therapeutics(TENX): had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year, while it had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings). Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 13 Nov 2025
Short interest and volume: Short interest spike, became public on 26 Nov 2025
Insiders: Clustered insider buying, became public on 6 Dec 2025
Short interest and volume: Short interest spike, became public on 10 Dec 2025
The 14 Nov 2025 report against the 24 reports before it.
this reportearliernormal: 319KSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 13 Nov 2025
Tenax Therapeutics had 762K shares sold short in the 31 Oct 2025 report, 7.2× the same report last year.
This period
762K (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
311K
Typical spread (median absolute deviation)
58K
How far from its usual level
+5.3
Same report last year
106K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 311K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Tenax Therapeutics had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year.
This period
758K (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
319K
Typical spread (median absolute deviation)
50K
How far from its usual level
+5.9
Same report last year
121K
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 319K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Insiders: Clustered insider buying became public on 6 Dec 2025
Tenax Therapeutics had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings).
Independent buyers
4
Purchase filings (Form 4, code P)
4
Total bought
$139K
Window
6 Nov 2025 to 6 Dec 2025
Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953)dated 19 Nov 2025, public 20 Nov 2025
MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180)dated 19 Nov 2025, public 20 Nov 2025
Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993)dated 20 Nov 2025, public 21 Nov 2025
Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630)dated 5 Dec 2025, public 6 Dec 2025
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Tenax Therapeutics had 600K shares sold short in the 28 Nov 2025 report, 4.6× the same report last year.
This period
600K (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
331K
Typical spread (median absolute deviation)
47K
How far from its usual level
+3.9
Same report last year
131K
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 331K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
11 Nov 2026Short interest and volume change
had 5.8M shares sold short in the 30 Oct 2026 report, 7.6× the same report last year.
Same report last year: 762K; its normal report is 760K.
See the evidence
This period
5.8M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
760K
Typical spread (median absolute deviation)
622K
How far from its usual level
+5.5
Same report last year
762K
History used
3,227 days
the 30 Oct 2026 report24 earlier reportsnormal: 760K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.2M shares sold short in the 15 Oct 2026 report, 9.6× the same report last year.
Same report last year: 754K; its normal report is 756K.
See the evidence
This period
7.2M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
756K
Typical spread (median absolute deviation)
593K
How far from its usual level
+7.4
Same report last year
754K
History used
3,212 days
the 15 Oct 2026 report24 earlier reportsnormal: 756K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 7.2M shares sold short in the 30 Sep 2026 report, 13× the same report last year.
Same report last year: 554K; its normal report is 743K.
See the evidence
This period
7.2M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
743K
Typical spread (median absolute deviation)
559K
How far from its usual level
+7.8
Same report last year
554K
History used
3,197 days
the 30 Sep 2026 report24 earlier reportsnormal: 743K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.5M shares sold short in the 15 Sep 2026 report, 20× the same report last year.
Same report last year: 275K; its normal report is 666K.
See the evidence
This period
5.5M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
666K
Typical spread (median absolute deviation)
470K
How far from its usual level
+6.9
Same report last year
275K
History used
3,182 days
the 15 Sep 2026 report24 earlier reportsnormal: 666K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year, while it had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings). Two unrelated kinds of activity within 91 days.
See the evidence (8 changes)
Short interest and volume: Short interest spike became public on 12 Aug 2026
Tenax Therapeutics had 2.6M shares sold short in the 31 Jul 2026 report, 7.6× the same report last year.
This period
2.6M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
433K
Typical spread (median absolute deviation)
303K
How far from its usual level
+4.7
Same report last year
335K
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 433K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Aug 2026
Tenax Therapeutics had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year.
This period
5.5M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
542K
Typical spread (median absolute deviation)
258K
How far from its usual level
+12.9
Same report last year
327K
History used
3,150 days
the 14 Aug 2026 report24 earlier reportsnormal: 542K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Sep 2026
Tenax Therapeutics had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year.
This period
9.3M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
577K
Typical spread (median absolute deviation)
341K
How far from its usual level
+17.2
Same report last year
298K
History used
3,167 days
the 31 Aug 2026 report24 earlier reportsnormal: 577K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Insiders: Clustered insider buying became public on 16 Sep 2026
Tenax Therapeutics had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings).
Independent buyers
3
Purchase filings (Form 4, code P)
5
Total bought
$4.8M
Window
17 Aug 2026 to 16 Sep 2026
Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M)dated 24 Aug 2026, public 25 Aug 2026
Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M)dated 2 Sep 2026, public 3 Sep 2026
ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M)dated 8 Sep 2026, public 9 Sep 2026
Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107)dated 15 Sep 2026, public 16 Sep 2026
STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010)dated 15 Sep 2026, public 16 Sep 2026
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 25 Sep 2026
Tenax Therapeutics had 5.5M shares sold short in the 15 Sep 2026 report, 20× the same report last year.
This period
5.5M (the 15 Sep 2026 report)
Normal report (median of 24 earlier)
666K
Typical spread (median absolute deviation)
470K
How far from its usual level
+6.9
Same report last year
275K
History used
3,182 days
the 15 Sep 2026 report24 earlier reportsnormal: 666K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Oct 2026
Tenax Therapeutics had 7.2M shares sold short in the 30 Sep 2026 report, 13× the same report last year.
This period
7.2M (the 30 Sep 2026 report)
Normal report (median of 24 earlier)
743K
Typical spread (median absolute deviation)
559K
How far from its usual level
+7.8
Same report last year
554K
History used
3,197 days
the 30 Sep 2026 report24 earlier reportsnormal: 743K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Oct 2026
Tenax Therapeutics had 7.2M shares sold short in the 15 Oct 2026 report, 9.6× the same report last year.
This period
7.2M (the 15 Oct 2026 report)
Normal report (median of 24 earlier)
756K
Typical spread (median absolute deviation)
593K
How far from its usual level
+7.4
Same report last year
754K
History used
3,212 days
the 15 Oct 2026 report24 earlier reportsnormal: 756K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 Nov 2026
Tenax Therapeutics had 5.8M shares sold short in the 30 Oct 2026 report, 7.6× the same report last year.
This period
5.8M (the 30 Oct 2026 report)
Normal report (median of 24 earlier)
760K
Typical spread (median absolute deviation)
622K
How far from its usual level
+5.5
Same report last year
762K
History used
3,227 days
the 30 Oct 2026 report24 earlier reportsnormal: 760K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
16 Sep 2026Insiders change
had 3 insiders buy $4.8M of its shares on the open market within 30 days (5 filings).
Who bought: Giordano Christopher Thomas, Staab Thomas R Ii.
See the evidence (5 source records)
Independent buyers
3
Purchase filings (Form 4, code P)
5
Total bought
$4.8M
Window
17 Aug 2026 to 16 Sep 2026
Schneeberger Daniel (ten percent owner) and 1 other(s) bought 1,025,867 shares of TENX ($1.8M)dated 24 Aug 2026, public 25 Aug 2026
Schneeberger Daniel (ten percent owner) and 1 other(s) bought 770,333 shares of TENX ($1.4M)dated 2 Sep 2026, public 3 Sep 2026
ADAR1 Capital Management, LLC (ten percent owner) and 1 other(s) bought 900,000 shares of TENX ($1.6M)dated 8 Sep 2026, public 9 Sep 2026
Giordano Christopher Thomas (CEO) bought 10,850 shares of TENX ($20,107)dated 15 Sep 2026, public 16 Sep 2026
STAAB THOMAS R II (Chief Financial Officer) bought 5,675 shares of TENX ($11,010)dated 15 Sep 2026, public 16 Sep 2026
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 9.3M shares sold short in the 31 Aug 2026 report, 31× the same report last year.
Same report last year: 298K; its normal report is 577K.
See the evidence
This period
9.3M (the 31 Aug 2026 report)
Normal report (median of 24 earlier)
577K
Typical spread (median absolute deviation)
341K
How far from its usual level
+17.2
Same report last year
298K
History used
3,167 days
the 31 Aug 2026 report24 earlier reportsnormal: 577K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 5.5M shares sold short in the 14 Aug 2026 report, 17× the same report last year.
Same report last year: 327K; its normal report is 542K.
See the evidence
This period
5.5M (the 14 Aug 2026 report)
Normal report (median of 24 earlier)
542K
Typical spread (median absolute deviation)
258K
How far from its usual level
+12.9
Same report last year
327K
History used
3,150 days
the 14 Aug 2026 report24 earlier reportsnormal: 542K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.6M shares sold short in the 31 Jul 2026 report, 7.6× the same report last year.
Same report last year: 335K; its normal report is 433K.
See the evidence
This period
2.6M (the 31 Jul 2026 report)
Normal report (median of 24 earlier)
433K
Typical spread (median absolute deviation)
303K
How far from its usual level
+4.7
Same report last year
335K
History used
3,136 days
the 31 Jul 2026 report24 earlier reportsnormal: 433K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
saw 30 13F filers open a new position in the quarter ended 31 Mar 2026, 7.5× the same quarter last year.
Same quarter last year: 4; its normal quarter is 4.5.
See the evidence
This period
30 (the quarter ended 31 Mar 2026)
Normal quarter (median of 8 earlier)
4.5
Typical spread (median absolute deviation)
2
How far from its usual level
+8.5
Same quarter last year
4
History used
4,200 days
the quarter ended 31 Mar 20268 earlier quartersnormal: 4.5
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
had 600K shares sold short in the 28 Nov 2025 report, 4.6× the same report last year.
Same report last year: 131K; its normal report is 331K.
See the evidence
This period
600K (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
331K
Typical spread (median absolute deviation)
47K
How far from its usual level
+3.9
Same report last year
131K
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 331K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year, while it had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings). Two unrelated kinds of activity within 28 days.
See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 13 Nov 2025
Tenax Therapeutics had 762K shares sold short in the 31 Oct 2025 report, 7.2× the same report last year.
This period
762K (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
311K
Typical spread (median absolute deviation)
58K
How far from its usual level
+5.3
Same report last year
106K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 311K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Nov 2025
Tenax Therapeutics had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year.
This period
758K (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
319K
Typical spread (median absolute deviation)
50K
How far from its usual level
+5.9
Same report last year
121K
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 319K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Insiders: Clustered insider buying became public on 6 Dec 2025
Tenax Therapeutics had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings).
Independent buyers
4
Purchase filings (Form 4, code P)
4
Total bought
$139K
Window
6 Nov 2025 to 6 Dec 2025
Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953)dated 19 Nov 2025, public 20 Nov 2025
MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180)dated 19 Nov 2025, public 20 Nov 2025
Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993)dated 20 Nov 2025, public 21 Nov 2025
Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630)dated 5 Dec 2025, public 6 Dec 2025
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
Short interest and volume: Short interest spike became public on 10 Dec 2025
Tenax Therapeutics had 600K shares sold short in the 28 Nov 2025 report, 4.6× the same report last year.
This period
600K (the 28 Nov 2025 report)
Normal report (median of 24 earlier)
331K
Typical spread (median absolute deviation)
47K
How far from its usual level
+3.9
Same report last year
131K
History used
2,891 days
the 28 Nov 2025 report24 earlier reportsnormal: 331K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
6 Dec 2025Insiders change
had 4 insiders buy $139K of its shares on the open market within 30 days (4 filings).
Who bought: Almenoff June Sherie, Mcgauley Thomas, Giordano Christopher Thomas, Rich Stuart.
See the evidence (4 source records)
Independent buyers
4
Purchase filings (Form 4, code P)
4
Total bought
$139K
Window
6 Nov 2025 to 6 Dec 2025
Almenoff June Sherie (director) bought 1,993 shares of TENX ($14,953)dated 19 Nov 2025, public 20 Nov 2025
MCGAULEY THOMAS (Interim CFO) bought 8,000 shares of TENX ($58,180)dated 19 Nov 2025, public 20 Nov 2025
Giordano Christopher Thomas (CEO) bought 2,605 shares of TENX ($19,993)dated 20 Nov 2025, public 21 Nov 2025
Rich Stuart (Chief Medical Officer) bought 5,000 shares of TENX ($45,630)dated 5 Dec 2025, public 6 Dec 2025
Fires when at least 3 independent insiders (joint filers count once) buy on the open market in 30 days, in at least 2 filings, for $100K or more in total; amendments do not count.
had 758K shares sold short in the 14 Nov 2025 report, 6.3× the same report last year.
Same report last year: 121K; its normal report is 319K.
See the evidence
This period
758K (the 14 Nov 2025 report)
Normal report (median of 24 earlier)
319K
Typical spread (median absolute deviation)
50K
How far from its usual level
+5.9
Same report last year
121K
History used
2,877 days
the 14 Nov 2025 report24 earlier reportsnormal: 319K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 762K shares sold short in the 31 Oct 2025 report, 7.2× the same report last year.
Same report last year: 106K; its normal report is 311K.
See the evidence
This period
762K (the 31 Oct 2025 report)
Normal report (median of 24 earlier)
311K
Typical spread (median absolute deviation)
58K
How far from its usual level
+5.3
Same report last year
106K
History used
2,863 days
the 31 Oct 2025 report24 earlier reportsnormal: 311K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 754K shares sold short in the 15 Oct 2025 report, 36× the same report last year.
Same report last year: 21K; its normal report is 310K.
See the evidence
This period
754K (the 15 Oct 2025 report)
Normal report (median of 24 earlier)
310K
Typical spread (median absolute deviation)
58K
How far from its usual level
+5.1
Same report last year
21K
History used
2,847 days
the 15 Oct 2025 report24 earlier reportsnormal: 310K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 113 entries; narrow the window or the kind of data to see older ones.
Not listed: 115 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000034956
Ticker
TENX
Domain
tenaxthera.com
Hq location
NC|CHAPEL HILL|27517 (1 unverified)
Name
OXYGEN BIOTHERAPEUTICS, INC., SYNTHETIC BLOOD INTERNATIONAL INC, Tenax Therapeutics, Inc.
Uei
N5YWD27TA8U6
SEC Form 13F institutional holdings441 data points30 Sep 2014 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)160 records14 Mar 2016 to 5 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)911 data points25 May 1967 to 31 Oct 2026
SEC Form 4 insider transactions25 records, 84 data points19 Feb 2016 to 21 Oct 2026
FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4174 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards1 record, 57 data points10 Sep 2008 to 19 Sep 2016